Stephanie L. Graff, MD, provides an overview of ESR1 mutations in ER+/HER2- metastatic breast cancer, highlighting their prevalence, clinical implications, and challenges.
Dr Langer reviews how physicians can ensure that patients get access to oral selective estrogen receptor degraders (SERDs), and the panel of experts provide their closing thoughts.
Dr Langer explores how payers think about the authorization process for DEXA scans and other surveillance activities that would be required for selective estrogen receptor degraders (SERDs) and how oral SERDs affect quality of life.
Drs Vidula and Lu review the potential impact of cardiovascular health associated with oral selective estrogen receptor degraders (SERDs) and discuss how the risk of menopausal symptoms differ between oral SERDs and other endocrine therapies.